At a glance
ClinicalIndex Comparison RecordN/ACompleted· 26,774 enrolled
Drug / intervention
Empagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cardiovascular Outcomes, and Mortality in Danish Patients With Type 2 Diabetes Who Initiate Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA): A Danish Nationwide Comparative Effectiveness Study [EMPLACEtm]
In Brief
An observational study evaluating Empagliflozin and Liraglutide for Diabetes Mellitus, Type 2. Completed, enrolled 26,774 participants across 1 site.
Detailed Summary
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesDenmark
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartOct 2018
First PostedJun 2019
Primary CompletionJun 2022
TodayJul 2026
First PostedJun 20, 2019
Enrollment StartOct 1, 2018
Primary CompletionJun 16, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.0 years ago
Interventions
Empagliflozindrug
new users (initiators) of Empagliflozin
Liraglutidedrug
initiators of Liraglutide